INTRODUCTION: Antibiotic resistance is the single biggest threat in the area of Infectious disease. Members of the family Enterobactericiae and Nonfermentors are the most frequently isolated bacterial human pathogens from clinical samples and this Gram negative bacilli acquiring Multidrug resistance (MDR) is a matter of concern. Carbapenams was first introduced in 1980[1] and are the most potent agents for the treatment of multi drug resistant gram negative bacilli infection ,particularly drug of choice for MDR Pseudomonas and ESBL producing Enterobactericiae Infections. It’s now frequently used as a last choice in treating such serious infections. Resistance to Imepenam started emerging from 1990 and has been reported worldwide in various frequencies [1, 2]. Information on Prevalence of resistance to Imepenam in clinical isolates from our country is also increasing. In the current situation of increased resistance it is essential to identify and report sensitivity pattern of these resistant bacteria in order to tailor empirical therapy and hygienic measures. Knowledge is needed on the local prevalence rate and how to change antibiotic prescription patterns to reduce selection and spread of these multi drug resistant pathogens. Moreover, because there will be no new antibiotics in the near future, a better understanding is needed on the how to optimize the use of existing antibiotics, alone and in combination with other drugs. Hence our aim was to do a retrospective analysis of Imepenam resistance rate among selected gram negative bacilli, especially Pseudomonas aeruginosa, ESBL E.coli, ESBL Klebsiella pneumoniae at our Tertiary care center. MATERIALS & METHODS: Retrospective analysis of Imepenam resistance was done over a peri... ... middle of paper ... ...ion of metallo beta lactamase producing Pseudomonas aeruginosa.Indian Journal of medical Microbiology,2010:28-3;241-4 15. Ullah et al.Antimicrobial susceptibility pattern and ESBL prevalence in Klebsiella pneumoniae from urinary tract infections in the North-West of Pakistan. African Journal of Microbiology Research. November 2009: 3 (11); 676-680 16. S Bhattacharya. ESBL - from petri dish to the patient.Indian Journal of Medical Microbiology, (2006) 24 (1):20-4. 17. Epidemiology and clinical features of infections caused by ESBL producing Escherichia coli in nonhospitalised patients. Journal of Clinical microbiology, Mar. 2004, p. 1089-1094. 18. Laupland, K.B., Church, D.L., Vidakovich, J., Mucenski, M. &Pitout, J.D. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 57, 441-448 (2008).